This product is a second-generation sulfonylurea hypoglycemic drug.

Gliclaclazide inhibits hepatic glucose production and output by stimulating pancreatic islet β cells to promote insulin secretion and increase insulin release after ingestion of glucose. This product can reduce the viscosity and aggregation of platelets, accelerate the fibrinolysis process, and help prevent and treat diabetic microangiopathy.

Primary Indications

For type II diabetes

The Main Contraindication To Medication

1. Patients with liver and kidney insufficiency are disabled.

2. Those who are allergic to sulfonylureas are prohibited.

3. Porphyria patients are prohibited: there will be pigment (porphyrin) accumulation in the body.

4. Patients treated with miconazole are contraindicated.

Tablets